Pharming Group

PHAR

Market cap $898M

Leiden, the Netherlands, July 16, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the second quarter and first half 2026 and provide a business update on Thursday, July 30, 2026.

Pharming today announced that the U.S. FDA accepted its sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS

Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York. Thursday June 4, 2026 at 11:05 EDT/17:05 CEST.

Pharming Group announced that shareholders approved all proposals presented at its Annual General Meeting of Shareholders (AGM), held on May 28, 2026.

Pharming Group NASDAQ: PHAR executives said first-quarter 2026 results reflected an expected decline in RUCONEST revenue tied largely to specialty pharmacy inventory movements and the company's planned exit from certain non-U.S. markets, while Joenja continued to post strong growth and the company advanced regulatory and clinical milestones across its pipeline. Get Pharming Group alerts:Sign UpRUCONEST revenue declined as inventory dynamics played out CEO Fabrice Chouraqui said quarterly revenue fell primarily due to RUCONEST, a decline he said was “largely expected due to inventory drawdown at specialty pharmacy,” which the company previously discussed on its fourth-quarter 2025 call.

Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript

Leiden, the Netherlands, May 7, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 6-9 in New Orleans, LA.

Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026.

Leiden, the Netherlands, April 23, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the first quarter 2026 and provide a business update on Thursday, May 7, 2026.

Pharming Group N.V. 2026 Annual General Meeting to be be held on Thursday May 28, 2026, at 14:00 CET. Meeting documents available on website Pharming.com.